• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Scholar Rock Holding Corporation

    2/12/25 9:30:58 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SRRK alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 8)


    SCHOLAR ROCK HLDG CORP

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    80706P103

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    80706P103


    1Names of Reporting Persons

    FMR LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    14,112,783.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    14,114,029.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    14,114,029.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    15.0 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    80706P103


    1Names of Reporting Persons

    Abigail P. Johnson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    14,114,029.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    14,114,029.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    15.0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    SCHOLAR ROCK HLDG CORP
    (b)Address of issuer's principal executive offices:

    301 BINNEY STREET, 3RD FLOOR,CAMBRIDGE,MA,USA,02142
    Item 2. 
    (a)Name of person filing:

    FMR LLC
    (b)Address or principal business office or, if none, residence:

    245 Summer Street, Boston, Massachusetts 02210
    (c)Citizenship:

    Not applicable
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    80706P103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    14114029.00
    (b)Percent of class:

    15.0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Please see the responses to Items 5 and 6 on the cover page.

     (ii) Shared power to vote or to direct the vote:

    0.00

     (iii) Sole power to dispose or to direct the disposition of:

    14114029.00

     (iv) Shared power to dispose or to direct the disposition of:

    0.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of SCHOLAR ROCK HLDG CORP. The interest of Fidelity Growth Company Commingled Pool, in the COMMON STOCK of SCHOLAR ROCK HLDG CORP, amounted to 4903393.00 shares or 5.2% of the total outstanding COMMON STOCK at 12/31/2024.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See attached Exhibit 99.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    FMR LLC
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
    Date:02/11/2025
     
    Abigail P. Johnson
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
    Date:02/11/2025

    Comments accompanying signature:  * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003.** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Exhibit Information

    Please see Exhibit 99 for 13d-1(k) (1) agreement.

    Get the next $SRRK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRRK

    DatePrice TargetRatingAnalyst
    1/9/2026$55.00Buy
    Citigroup
    11/18/2025$42.00Outperform
    Wolfe Research
    10/9/2025$53.00Buy
    BofA Securities
    9/17/2025$45.00Overweight
    Barclays
    9/15/2025$51.00Outperform
    Leerink Partners
    8/21/2025$50.00Buy
    Jefferies
    7/30/2025$53.00Strong Buy
    Raymond James
    7/17/2025Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SRRK
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Scholar Rock Holding Corporation

    SCHEDULE 13G - Scholar Rock Holding Corp (0001727196) (Subject)

    2/10/26 11:19:49 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock Holding Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Scholar Rock Holding Corp (0001727196) (Filer)

    1/12/26 9:23:39 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock Holding Corporation filed SEC Form 8-K: Other Events

    8-K - Scholar Rock Holding Corp (0001727196) (Filer)

    12/2/25 7:00:38 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President of R&D Vaishnaw Akshay was granted 47,021 shares, increasing direct ownership by 8% to 642,788 units (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    2/11/26 6:13:09 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Sinha Vikas was granted 47,021 shares, increasing direct ownership by 8% to 630,266 units (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    2/11/26 6:12:17 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Scientific Officer Qatanani Mo was granted 29,258 shares, increasing direct ownership by 34% to 114,918 units (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    2/11/26 6:11:20 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Akkaraju Srinivas bought $1,181,634 worth of shares (29,599 units at $39.92) and exercised 1,064,804 in-the-money shares at a strike of $7.35 (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    12/16/25 9:07:57 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Akkaraju Srinivas bought $18,807,352 worth of shares (500,439 units at $37.58) (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    10/7/25 8:59:19 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Akkaraju Srinivas bought $15,000,000 worth of shares (2,189,781 units at $6.85) (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    10/18/23 5:46:02 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the Company granted inducement equity awards covering an aggregate of 114,668 shares of its common stock to seven newly hired employees, consisting of inducement stock options to purchase an aggregate of 64,226 shares of common stock and inducement restricted stock units, covering an aggregate of 50,442 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is us

    2/13/26 4:15:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

    Scholar Rock (NASDAQ:SRRK) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026, before the financial markets open. The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to "Events and Presentations" in the Investors section of the Scholar Rock website at http://investors.scholarrock.com. To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call. An archived replay of the webcast will be available on the Company's

    2/10/26 8:00:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the company granted inducement equity awards covering an aggregate of 35,200 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 20,400 shares of common stock and inducement restricted stock units, covering an aggregate of 14,800 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is used

    1/16/26 4:15:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Scholar Rock with a new price target

    Citigroup initiated coverage of Scholar Rock with a rating of Buy and set a new price target of $55.00

    1/9/26 9:07:37 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wolfe Research initiated coverage on Scholar Rock with a new price target

    Wolfe Research initiated coverage of Scholar Rock with a rating of Outperform and set a new price target of $42.00

    11/18/25 8:27:21 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BofA Securities initiated coverage on Scholar Rock with a new price target

    BofA Securities initiated coverage of Scholar Rock with a rating of Buy and set a new price target of $53.00

    10/9/25 8:29:07 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 9:00:58 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 7:24:55 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 1:22:38 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Financials

    Live finance-specific insights

    View All

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the Company granted inducement equity awards covering an aggregate of 114,668 shares of its common stock to seven newly hired employees, consisting of inducement stock options to purchase an aggregate of 64,226 shares of common stock and inducement restricted stock units, covering an aggregate of 50,442 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is us

    2/13/26 4:15:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

    Scholar Rock (NASDAQ:SRRK) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026, before the financial markets open. The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to "Events and Presentations" in the Investors section of the Scholar Rock website at http://investors.scholarrock.com. To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call. An archived replay of the webcast will be available on the Company's

    2/10/26 8:00:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the company granted inducement equity awards covering an aggregate of 35,200 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 20,400 shares of common stock and inducement restricted stock units, covering an aggregate of 14,800 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is used

    1/16/26 4:15:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Leadership Updates

    Live Leadership Updates

    View All

    Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer

    - Former Vice President and Global HR Head of Oncology and Pharma Development at Novartis brings extensive leadership experience focused on talent, culture, and diversity Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Caryn Parlavecchio as Chief Human Resources Officer. She will join the executive team, bringing more than 20 years of experience as a senior leader and strategic executive in the biotechnology and pharmaceutical industries. This press release features multimedia. View the full release here: https://www.businesswire.co

    8/16/21 4:05:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care